Advertisement
Advertisement
ALVO
Alvotech Ordinary Shares
3.63
USDSponsored
+0.02
+0.69%
Apr 10, 15:59 UTC -4
Closed
After-Market
3.62
0.00
-0.14%
ALVO Earnings Reports
Positive Surprise Ratio
ALVO beat 5 of 10 last estimates.
50%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$143.66M
/$0.03
Implied change from Q4 25 (Revenue/ EPS)
-14.94%
/-108.11%
Implied change from Q1 25 (Revenue/ EPS)
+8.18%
/-91.43%
Alvotech Ordinary Shares earnings per share and revenue
On Mar 18, 2026, ALVO reported earnings of -0.37 USD per share (EPS) for Q4 25, missing the estimate of -0.04 USD, resulting in a -706.10% surprise. Revenue reached 168.90 million, compared to an expected 163.13 million, with a 3.54% difference. The market reacted with a -5.79% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 4 analysts forecast an EPS of 0.03 USD, with revenue projected to reach 143.66 million USD, implying an decrease of -108.11% EPS, and decrease of -14.94% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Palvella Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.92
Actual
-$1.07
Surprise
-15.20%
Nanobiotix S.A. - ADR
Report Date
Mar 31, 2026 For Q4 25
Estimate
$0.55
Actual
-$0.39
Surprise
-170.16%
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.44
Actual
-$1.91
Surprise
-32.66%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
MiNK Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.83
Actual
-$0.55
Surprise
+33.64%
Cyclerion Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.38
Actual
-$0.21
Surprise
+45.82%
Kairos Pharma, Ltd.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.07
Surprise
-28.68%
Cadrenal Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.18
Actual
-$1.43
Surprise
-20.34%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
FAQ
What were Alvotech Ordinary Shares's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Alvotech Ordinary Shares reported EPS of -$0.37, missing estimates by -706.1%, and revenue of $168.90M, 3.54% above expectations.
How did the market react to Alvotech Ordinary Shares's Q4 2025 earnings?
The stock price moved down -5.79%, changed from $3.80 before the earnings release to $3.58 the day after.
When is Alvotech Ordinary Shares expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Alvotech Ordinary Shares's next earnings report?
Based on 4
analysts, Alvotech Ordinary Shares is expected to report EPS of $0.03 and revenue of $143.66M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement